Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.470
-0.090 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
3.264
-0.206 (-5.95%)
After-hours: Apr 28, 2026, 7:51 PM EDT
Exicure Employees
Exicure had 8 employees as of December 31, 2025. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$618,250
Market Cap
22.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| OSR Holdings | 22 |
| Barinthus Biotherapeutics | 14 |
| Serina Therapeutics | 13 |
| VYNE Therapeutics | 10 |
| Allarity Therapeutics | 8 |
XCUR News
- 6 days ago - Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - GlobeNewsWire
- 26 days ago - Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - GlobeNewsWire
- 4 weeks ago - Exicure, Inc. Reports Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - GlobeNewsWire
- 3 months ago - Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - GlobeNewsWire
- 5 months ago - Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial - Benzinga
- 5 months ago - Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting - GlobeNewsWire
- 6 months ago - Exicure, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire